Working...
ClinicalTrials.gov
ClinicalTrials.gov Menu
Trial record 72 of 303 for:    Recruiting, Not yet recruiting, Available Studies | Pediatrics

Safety,Efficacy and Pharmacokinetics Evaluation of SCT800 in Previously Treated Paediatric Patients With Severe Haemophilia A.

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details.
ClinicalTrials.gov Identifier: NCT03947320
Recruitment Status : Not yet recruiting
First Posted : May 13, 2019
Last Update Posted : May 13, 2019
Sponsor:
Information provided by (Responsible Party):
Sinocelltech Ltd.

Brief Summary:
This study is a multicenter phase III uncontrolled open-label trial to evaluate the efficacy,safety and pharmacokinetics of SCT800 in regular prophylaxis and perioperative treatment in patients (<12 years old) with severe hemophilia A who have been previously treated with coagulation factor VIII(FVIII) . This study includes two phases: the screening period and prophylaxis period.Prophylaxis with 25 - 50 IU/kg of SCT800 shall be administered once every other day or three times per week starting from Visit 1 and prophylaxis with SCT800 shall continue for 24 consecutive weeks.

Condition or disease Intervention/treatment Phase
Hemophilia A Drug: Recombinant Human Coagulation FVIII Phase 3

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Estimated Enrollment : 70 participants
Intervention Model: Single Group Assignment
Masking: None (Open Label)
Primary Purpose: Prevention
Official Title: A Multicenter Phase III Uncontrolled Open-label Trial to Evaluate Safety and Efficacy and Pharmacokinetics of Recombinant Human Coagulation Factor VIII (SCT800) in Previously Treated Paediatric Patients With Severe Haemophilia A.
Estimated Study Start Date : December 20, 2019
Estimated Primary Completion Date : September 20, 2020
Estimated Study Completion Date : September 20, 2020

Resource links provided by the National Library of Medicine

MedlinePlus related topics: Hemophilia

Arm Intervention/treatment
Experimental: Recombinant Human Coagulation FVIII
Participant receivedSCT800 for prophylaxis with 25 - 50 IU/kg injection once every other day or three times per week for 6 months.
Drug: Recombinant Human Coagulation FVIII
Participant received SCT800 for prophylaxis with 25 - 50 IU/kg injection once every other day or three times per week for 6 months.
Other Name: SCT800




Primary Outcome Measures :
  1. Annualized Bleeding Rate [ Time Frame: up to 24 weeks ]
    Annualized Bleeding Rate(ABR) can be calculated using the following formula: Number of bleeding events in efficacy evaluation period/(number of days in treatment period/365.25)


Secondary Outcome Measures :
  1. Annualized joint bleeding rate [ Time Frame: up to 24 weeks ]
    Annualized joint bleeding rate(AJBR) can be calculated using the following formula: Number of joint bleeding events during efficacy evaluation period/(number of days in treatment period/365.25).

  2. FVIII incremental in-vivo recovery [ Time Frame: Predose within 30 min,15 min±2 min ]
    Incremental recovery is determined as the peak factor level recorded in the first hour after infusion and is reported as [IU/ml]/[IU/kg]

  3. Bleeding event treatment efficacy [ Time Frame: up to 24 weeks ]
    The investigator shall evaluate the hemostatic effect after the treatment of every bleeding event of subjects based on a four-point scale(excellent, good, moderate, not relieved).

  4. Elimination Half Life [ Time Frame: Predose within 30 min,15 min±2 min、1 hour±5 min,10 hours±30 min,24 hours±1hours and 48 hours±2 hours post-dose ]
    t1/2; Chromogenic Assay

  5. Clearance [ Time Frame: Predose within 30 min,15 min±2 min、1 hour±5 min,10 hours±30 min,24 hours±1hours and 48 hours±2 hours post-dose ]
    CL; Chromogenic Assay


Other Outcome Measures:
  1. Incidence of FVIII inhibitors [ Time Frame: up tp 24 weeks ]
    The Nijmegen-Bethesda assay shall be used to monitor the production of FVIII inhibitors during the trial.



Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Layout table for eligibility information
Ages Eligible for Study:   up to 12 Years   (Child)
Sexes Eligible for Study:   Male
Gender Based Eligibility:   Yes
Gender Eligibility Description:   Hemophilia A is a kind of sex chromosome recessive genetic disease and ofter occurs in male.
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

  • Aged <12 years ;
  • Male severe (central laboratory tested FVIII:C <1%) hemophilia A patients;
  • Previously received FVIII treatment (prophylactic or bleeding treatment), have the relevant records and are verified to have accumulated EDs ≥150 days(6≤age<12years old)and EDs >50 days(age <6 years old);
  • The bleeding treatment records of at least 3 months before screening can be obtained;
  • Negative FVIII inhibitor assay results (laboratory tested Nijmegen-Bethesda assay result <0.6 BU/mL);
  • HIV negative; if HIV positive, the viral load <200 particles/uL or <400,000 copies/mL, and HIV patients must satisfy CD4+ count >200/μL;
  • The patient or his guardian voluntarily signed the Informed Consent Form.

Exclusion Criteria:

  • Known allergy to any coagulation factor VIII or any excipient; known allergy to bovine, rodent or hamster bovine;
  • Has a history or family history of blood coagulation factor VIII inhibitor;
  • Platelet count <100 × 109/L;
  • Clinical liver function test ((glutamic-pyruvic transaminase, glutamic-pyruvic transaminase) ≥ five times the upper limit of normal (ULN) or clinical kidney function test (creatinine) ≥ two times the ULN;
  • International normalized ratio (INR) >1.5;
  • Patients with other coagulation dysfunction diseases in addition to hemophilia A;
  • Patients who used any anticoagulant or anti-platelet treatment (including non-steroidal anti-inflammatory drugs [NSAIDs]) within 1 weeks before the first drug administration or who regularly (e.g., daily, every other day) use anticoagulant or anti-platelet treatment within the clinical trial period;
  • Patients who used immunomodulator(e.g., immunoglobulin, corticosteroids,alpha-interferon, prednisone [>10 mg/day and >7 days], or comparable drugs, other than anti-retroviral chemotherapy) within two weeks before the first administration of the study drug or during the clinical trial period;
  • Administration of any cryoprecipitate, whole blood or plasma within 30 days prior to administration of study drug.
  • Patients with other clinically significant diseases, alcoholism, drug abuse, mental disorders or intellectual disabilities;
  • Patients with other severe or clinical significant diseases verified by the investigator to be unable to benefit from the clinical study;
  • Patients who participated in other clinical studies within one month before the first drug administration (except FVIII trials) and patients who participated in other FVIII clinical trials after signing the Informed Consent Form;

Layout table for additonal information
Responsible Party: Sinocelltech Ltd.
ClinicalTrials.gov Identifier: NCT03947320     History of Changes
Other Study ID Numbers: SCT800-A303
First Posted: May 13, 2019    Key Record Dates
Last Update Posted: May 13, 2019
Last Verified: May 2019

Layout table for additional information
Studies a U.S. FDA-regulated Drug Product: No
Studies a U.S. FDA-regulated Device Product: No

Additional relevant MeSH terms:
Layout table for MeSH terms
Hemophilia A
Blood Coagulation Disorders, Inherited
Blood Coagulation Disorders
Hematologic Diseases
Coagulation Protein Disorders
Hemorrhagic Disorders
Genetic Diseases, Inborn
Factor VIII
Coagulants